Get the Stockscreener App
32.02
0.53%
0.17
After Hours:
32.02
Surrozen Inc stock is traded at $32.02, with a volume of 286.36K.
It is up +0.53% in the last 24 hours and up +27.01% over the past month.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
See More
Previous Close:
$31.85
Open:
$31.68
24h Volume:
286.36K
Relative Volume:
2.51
Market Cap:
$367.80M
Revenue:
$3.48M
Net Income/Loss:
$-259.96M
P/E Ratio:
-0.8628
EPS:
-37.1111
Net Cash Flow:
$-30.37M
1W Performance:
+23.49%
1M Performance:
+27.01%
6M Performance:
+132.87%
1Y Performance:
+228.41%
1-Day Range:
$30.36
$33.22
1-Week Range:
$25.11
$33.22
52-Week Range:
$5.90
$33.22
Surrozen Inc Stock (SRZN) Company Profile
Name
Surrozen Inc
Sector
Industry
Phone
650-475-2820
Address
171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO
Compare SRZN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRZN
Surrozen Inc
|
32.02 | 365.85M | 3.48M | -259.96M | -30.37M | -37.11 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Surrozen Inc Stock (SRZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-30-25 | Initiated | H.C. Wainwright | Buy |
| Jan-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Sep-15-21 | Initiated | Guggenheim | Buy |
| Sep-07-21 | Initiated | Stifel | Buy |
View All
Surrozen Inc Stock (SRZN) Latest News
Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains? - Yahoo Finance
(SRZN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Aug Ideas: How liquid is Surrozen Inc stock2026 Analyst Calls & Advanced Technical Signal Analysis - baoquankhu1.vn
SRZN Stock Price, Quote & Chart | SURROZEN INC (NASDAQ:SRZN) - ChartMill
Merck Wnt first, Surrozen goes next in AMD, DME - BioWorld News
Published on: 2026-04-08 02:43:17 - baoquankhu1.vn
SRZN PE Ratio & Valuation, Is SRZN Overvalued - Intellectia AI
Responsive Playbooks and the SRZN Inflection - Stock Traders Daily
Surrozen (SRZN) EVP Li Yang donates 1,666 common shares in Form 4 - Stock Titan
[ARS] Surrozen, Inc./DE SEC Filing - Stock Titan
Executive pay and board elections headline Surrozen (NASDAQ: SRZN) 2026 meeting - Stock Titan
[EFFECT] Surrozen, Inc./DE SEC Filing - Stock Titan
Surrozen (NASDAQ: SRZN) sets $50M ATM shelf with TD Cowen - Stock Titan
Short Squeeze: Should value investors consider Surrozen Inc Equity Warrant2026 Chart Watch & Long-Term Growth Stock Strategies - baoquankhu1.vn
Surrozen (NASDAQ:SRZN) Upgraded at Wall Street Zen - Defense World
Tcg Crossover Gp Ii, Llc Acquires 106,658 Shares of Surrozen (NASDAQ:SRZN) Stock - Defense World
What is Lifesci Capital’s Forecast for Surrozen Q1 Earnings? - Defense World
Breakout Zone: Is Surrozen Inc Equity Warrant attractive for institutional investorsRate Cut & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Wednesday’s insider activity: Major buys at Surrozen and MGM Resorts - Investing.com
Guggenheim Keeps Their Buy Rating on Surrozen (SRZN) - The Globe and Mail
What is Lifesci Capital's Forecast for Surrozen Q1 Earnings? - MarketBeat
What is HC Wainwright's Forecast for Surrozen Q1 Earnings? - MarketBeat
Guidance Update: Can Surrozen Inc Equity Warrant lead its sector in growth2026 Buyback Activity & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
HC Wainwright Forecasts Surrozen FY2030 Earnings - Defense World
Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Buys $2,633,386.02 in Stock - MarketBeat
Surrozen (NASDAQ:SRZN) Major Shareholder Buys $379,052.70 in Stock - MarketBeat
TCG Crossover funds boost Surrozen (SRZN) stake with open-market buys - stocktitan.net
TCG crossover funds buys Surrozen (SRZN) shares worth $3m By Investing.com - Investing.com South Africa
TCG crossover funds buys Surrozen (SRZN) shares worth $3m - Investing.com
Earnings Risk: Is Surrozen Inc a cyclical or defensive stock2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn
Cantor Fitzgerald Sticks to Their Buy Rating for Surrozen (SRZN) - The Globe and Mail
HC Wainwright Weighs in on Surrozen FY2030 Earnings - MarketBeat
Fed Meeting: Is Surrozen Inc Equity Warrant forming a bullish divergence2026 Price Momentum & Low Drawdown Trading Strategies - baoquankhu1.vn
SRZNW SEC FilingsSurrozen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: CSL (CMXHF), Surrozen (SRZN) - The Globe and Mail
Guggenheim reiterates Surrozen stock rating on pipeline progress By Investing.com - Investing.com Canada
Guggenheim reiterates Surrozen stock rating on pipeline progress - Investing.com UK
Cantor Fitzgerald Reaffirms Overweight Rating for Surrozen (NASDAQ:SRZN) - MarketBeat
Cantor Fitzgerald reiterates Overweight on Surrozen stock at $40 By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight on Surrozen stock at $40 - Investing.com UK
Surrozen's (SRZN) Buy Rating Reaffirmed at HC Wainwright - marketbeat.com
SRZN: HC Wainwright & Co. Raises Price Target to $36, Reiterates Buy Rating | SRZN Stock News - GuruFocus
Surrozen Reports 2025 Financial Results, Advances Retinal Disease Therapies, and Announces $5M Milestone from Boehringer Ingelheim - Minichart
Surrozen, Inc. 2025 Annual Report: Advancing Wnt Pathway Modulation for Ophthalmic Disease Treatment 50 - Minichart
Surrozen Reports Q4 and Full Year 2025 Financial Results, Provides Business UpdateSouth San Francisco Today - National Today
Surrozen (NASDAQ: SRZN) files $200M shelf to sell stock, debt, warrants - Stock Titan
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Investing News Network
Surrozen (NASDAQ:SRZN) Releases Earnings Results, Misses Expectations By $6.30 EPS - MarketBeat
Surrozen 10-K: Revenue $3.48M, EPS $(32.37) — steep net loss from financing charges - TradingView
[10-K] Surrozen, Inc./DE Files Annual Report - Stock Titan
Surrozen Inc Stock (SRZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):